4
Changes in Ownership
Cartesian Therapeutics, Inc. Filed Acc 0001453687-24-000140
Chief Technology Officer sold 38,689 shares at an average $16.78 ($649,030)
- Chief Technology Officer acquired 38,689 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kurtoglu Metin Chief Technology Officer | 2024-11-19 | Option exercise | +200 | $1.41 | $282 | 51,233 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-19 | Sale | −200 | $19.50 | $3,900 | 51,033 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-20 | Option exercise | +5,700 | $1.41 | $8,037 | 56,733 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-20 | Sale | −5,600 | $17.28 | $96,761 | 51,133 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-20 | Sale | −100 | $18.09 | $1,809 | 51,033 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-21 | Option exercise | +32,789 | $1.41 | $46,232 | 83,822 | D |
| Kurtoglu Metin Chief Technology Officer | 2024-11-21 | Sale | −32,789 | $16.67 | $546,560 | 51,033 | D |
| Derivatives | |||||||
| Kurtoglu Metin Chief Technology Officer | 2024-11-19 | Option exercise · Stock Option (Right to Buy) | −200 | 131,252 | D | ||
| Kurtoglu Metin Chief Technology Officer | 2024-11-20 | Option exercise · Stock Option (Right to Buy) | −5,700 | 125,552 | D | ||
| Kurtoglu Metin Chief Technology Officer | 2024-11-21 | Option exercise · Stock Option (Right to Buy) | −32,789 | 92,763 | D | ||
| Open-market sales · 38,689 sh · avg $16.78 · $649,030 | |||||||
Loading xslF345X05/wk-form4_1732233135.xml…